Breaking News:This Big Pharma Company Has Announced 1:1 Bonus Issue.

Anuh Pharma Share News: Here’s an overview of Anuh Pharma Ltd’s upcoming bonus share issue, recent performance, and future prospects:

🟢 Upcoming 1:1 Bonus Share Issue

Anuh Pharma Share News:

Announced: On May 23, 2025, the Board approved a 1:1 bonus issue, meaning shareholders will receive one additional fully paid ₹5 share for every one share held, doubling the share count upon record date confirmation
Financing: Drawn entirely from free reserves (₹300.85 crore as on Mar 31, 2025), with ₹25.06 crore earmarked for expansion of share capital
Timing & Approval: Final issuance is subject to shareholder approval via postal ballot. An official record date will be announced soon, and bonus shares are expected to be credited within two months of board approval
Dividend Impact: Alongside the bonus, the Board recommended a ₹1.50 per share dividend (30% on face value), payable on the post-bonus share capital

📉 Recent Financial Performance

Q4 FY25: Standalone net profit fell ~19% from ₹15.36 cr to ₹12.46 cr year‑on‑year
Q3 Concerns: Reports highlight declining profit before and after tax, triggering a mildly bearish market outlook and limited institutional interest
Cash Flow Pressure: MarketsMojo flagged weakening operating cash flow, prompting technical downgrade from “Very Attractive” to “Attractive” valuation
Valuation Levels: As of Feb 2025, P/E ~ 15.9, EV/EBITDA ~ 12.4, strong returns on capital (ROCE ~ 23.5%, ROE ~ 16.6%)

📈 Historical Strength & Technical Signals

Long-term Performance: Over the past 3 years, Anuh Pharma generated ~164% returns, with 20% quarterly revenue growth and 25%+ profit margins.
Price Momentum: The stock rose over 40% from its 52-week low of ₹148 to around ₹210–₹230; earlier, it hit a 52-week high of ₹213.75 (Feb 2024)
Technical Outlook: Trading above its 25- and 50-day moving averages, with short-term targets projected in the ₹224–₹231 range and medium-term technical momentum intact

🏗️ Strategic Growth Drivers

Capacity Expansion: ICRA upgraded its rating outlook to “Positive,” citing capacity increases—from 1,200 tpa to 1,500, then to 2,200 tpa for APIs—and strong accrual-based funding
Product Diversification & Approvals: Expanding into high-margin APIs (e.g., erythromycin ~32% revenue share), with EDQM (CEP) approvals for gliclazide and azithromycin opening European markets. Pipeline includes Ticagrelor, Dapagliflozin, Empagliflozin, Bilastine HCl, Pyronaridine tetraphosphate, Vonoprazan fumarate
R&D & Global Reach: SK‑Group‑backed, located in Tarapur, investing in lifestyle disease molecules (diabetes, hypertension, CNS, dermatology) and eyeing inorganic expansion/entry into markets like Vietnam, Japan, Brazil, North America

🔍 Future Outlook: Balancing Risks & Opportunities

Opportunities

Bonus/Dividend Boost — Shareholders gain dematerialized value and enhanced liquidity. The ₹1.50 dividend is attractive on the doubled share base.
Capacity & Portfolio Expansion — Increased API throughput and new high-value products could support sustained revenue gains.
Valuation Leverage — With earnings lagging technical upside, improved margins and cash flows may support valuation upgrades.

Risks

Profit Volatility — Q4 earnings dip and softer Q3 performance highlight margin pressures and cyclical demand.
Cash Flow Constraints — Ongoing capex may delay free cash flow recovery.
Market & Regulatory Exposure — API businesses face commoditization, pricing pressures, forex risks, and regulatory uncertainty

🧭 Summary-Anuh Pharma Share News:

Anuh Pharma is leveraging its 1:1 bonus issue and ₹1.50 dividend to reward shareholders amid a strong operational and strategic growth backdrop. The company’s manufacturing scale-up, pipeline diversification, and improving balance sheet—endorsed by ICRA’s “Positive” outlook—support medium-to‑long-term optimism. Still, recent profit softness and cash flow dynamics warrant close monitoring. For investors, the key is tracking Q1/FY26 results and free cash flow to confirm whether the bonus marks a turnaround or a consolidation phase.

Disclaimer: Investments in Capital Market/Share Prices are subject to market fluctuations and are dependent on several factors. These predictions are based on the current market conditions and the future market expectations. Investors are advised to take into consideration all these factors before making any investment in Capital Market. This article should not be treated as Investment advisory and is for general Guidance & Educational purpose only. We keep revising our share price targets based on the latest information available with us. Please keep visiting our website regularly to keep yourself updated. News4You does not offer investment advice and does not encourage any action based on its content.

How to make maximum profit with minimum investment from the Stock Market ? – MoneyInsight

Also Read :

How to make money from share market? (indiatimes.com)

AGLI DUNIYA: शेयर बाजार से पैसे कैसे कमाए ?

Visit our Website regularly for more such Educational Research Articles:

News4You – News & Views On Personal Finance & Share Market